A large real-world study shows lower all-cause mortality and some cardiovascular outcomes with combination therapy; other outcomes lack statistical precision.

Join Dr. Sara Nunnery, Director of Breast Cancer Research at Tennessee Oncology, on the “Breast Cancer Briefing” podcast. This series offers expert analysis of the latest breast cancer clinical trials ...

A new approach to weight loss research is challenging one of the biggest assumptions behind popular weight loss drugs: Are ...

Arthritis includes a range of conditions that affect the joints, from inflammatory diseases such as rheumatoid arthritis and ...

Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't ...

Researchers say knowing that semaglutide improves liver health independently of weight loss could influence prescribing decisions.

As more people turn to prescription drugs for smaller weight-loss goals, one writer explores the pros and cons.

In a new study exploring stigma associated with the use of GLP-1 drugs for weight loss, women who lost weight using GLP-1 ...

News and commentary from the endocrinology world ...

GLP-1 receptor agonists are everywhere and everybody is talking about them. Most of the orthopaedic discussions have been around when to stop them before surgery. That matters, but much more is being ...

GLP-1 receptor agonists are a gamechanger in obesity care, but researchers are still working to better understand their ...

A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again.